<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>How It Works | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <meta
    name="description"
    content="How LiquidMammo™ works: a microRNA-based blood test that complements breast cancer screening, especially in dense breast tissue."
  />

  <!-- Stylesheet -->
  assets/css/styles.css

  <!-- Favicon -->
  favicon.png
</head>

<body>

<!-- ======================================
     MINIMAL HEADER (← Home)
======================================= -->
<header class="container">
  <nav>
    index.html← Home</a>
  </nav>
</header>


<!-- ======================================
     MAIN CONTENT
======================================= -->
<main class="container">

  <h1>How LiquidMammo™ Works</h1>

  <!-- Overview -->
  <section class="section-tight">
    <p>
      LiquidMammo™ is a supplemental blood‑based test that analyzes
      <strong>cancer‑associated microRNA signatures</strong> to support breast‑cancer screening.
      It is designed to complement mammography and is especially relevant for
      <strong>dense‑breast populations</strong>.
    </p>

    <p class="notice" style="margin-top:14px;">
      LiquidMammo is being developed as a
      <strong>CLIA Laboratory Developed Test (LDT)</strong>.
      It is not yet FDA‑cleared or FDA‑approved.
    </p>
  </section>


  <!-- Step-by-step -->
  <section class="panel-light section-tight">
    <h2>The process</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:18px;">

      <div class="card-mini">
        <h4>1 — Ordered by clinician</h4>
        <p class="small">
          The test is ordered through a clinician, similar to routine laboratory assays.
          A standard blood draw is all that is required.
        </p>
      </div>

      <div class="card-mini">
        <h4>2 — Plasma processing</h4>
        <p class="small">
          Blood samples are processed under SOP‑driven laboratory workflows to isolate
          stable circulating <span class="scientific-term">microRNAs</span>.
        </p>
      </div>

      <div class="card-mini">
        <h4>3 — microRNA panel analysis</h4>
        <p class="small">
          A proprietary multi‑marker panel quantifies dysregulation patterns associated
          with tumor biology and oncogenic pathways.
        </p>
      </div>

      <div class="card-mini">
        <h4>4 — Classification & interpretation</h4>
        <p class="small">
          Machine‑learning classification integrates molecular signals with reference
          distributions, producing a density‑aware interpretation.
        </p>
      </div>

      <div class="card-mini">
        <h4>5 — Clinician‑ready report</h4>
        <p class="small">
          The final report includes result category, contextual notes for density, and
          guidance for appropriate follow‑up actions.
        </p>
      </div>

    </div>
  </section>


  <!-- Biological rationale -->
  <section class="section-tight">
    <h2>Why microRNAs?</h2>
    <p>
      <span class="scientific-term">microRNAs</span> regulate gene expression and are involved in
      cancer‑associated processes such as proliferation, immune modulation, and metastatic
      signaling. They are stable in blood and can show early dysregulation — sometimes before
      structural changes are detected through imaging.
    </p>
  </section>


  <!-- Density challenges -->
  <section class="panel-light section-tight">
    <h2>Addressing dense‑breast limitations</h2>
    <ul class="list-tight">
      <li>Mammography sensitivity may fall to ~61% in extremely dense tissue.</li>
      <li>Dense tissue can mask small or early‑stage lesions.</li>
      <li>Interval cancers are more common in dense‑breast populations.</li>
      <li>A molecular signal provides consistency across varying breast density.</li>
    </ul>
  </section>


  <!-- Ideal clinical role -->
  <section class="section-tight">
    <h2>The role of LiquidMammo in clinical pathways</h2>
    <p class="small">
      LiquidMammo is designed as a supplemental tool — not a replacement for imaging. It helps
      strengthen screening workflows by adding a biologically driven layer of information.
    </p>

    <ul class="list-tight" style="margin-top:10px;">
      <li>Triaging equivocal imaging results.</li>
      <li>Supporting decision‑making for dense‑breasted patients.</li>
      <li>Adding molecular signal for patients who defer imaging.</li>
      <li>Enhancing confidence in routine screening pathways.</li>
    </ul>
  </section>

</main>


<!-- ======================================
     FOOTER
======================================= -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC,
        and operates out of LabCentral in Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end; text-align:right;">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br/>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy & Compliance</a> •
    contact.htmlOrder / Kits</a>
  </div>
</footer>

</body>
</html>


